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Abstract: Purpose: With the increasing number of therapy options available for patients with lung
cancer, early response evaluation is needed. We performed this pilot study to assess the feasibility of
early, repeated Positron emission tomography-magnetic resonance (PET/MR), the impact of timing
and the capability for response prediction in lung tumors during chemotherapy. Methods: Patients
with stage IV non-small cell lung cancer referred for chemotherapy were prospectively recruited.
Fluorine-18-Fluorodeoxyglucose(18F-FDG)-PET/MR scans were performed prior to, during and
after the first or second cycle of chemotherapy. Primary tumors were defined on all scans and size,
FDG-uptake and apparent diffusion coefficient (ADC) were measured. Early response was described
over time and a Standard Linear Mixed Model was applied to analyze changes over time. Results: 45
FDG-PET/MR scans were performed in 11 patients. Whereas the overall changes measured by ADC
did not change significantly, there was an overall significant decrease in FDG-uptake from pre to post
treatment scans. There was no difference in the FDG-uptake measured 1 or 3 weeks after therapy, but
uptake measured 2 weeks after therapy differed from measurements at week 3. Changes measured in
patients scanned during the first treatment cycle appeared more pronounced than during the second
cycle. Conclusions: This pilot study indicates that response evaluation shortly after initiation of
chemotherapy appears concordant with later evaluation and probably more reliable than evaluation
midway between cycles. Responses during or after the first cycle of chemotherapy rather than during
subsequent cycles are likely to be more readily measured.
Keywords: response evaluation; lung cancer; non-small-cell lung carcinoma (NSCLC); FDG-PET;
diffusion weighted magnetic resonance imaging (DW-MRI)
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1. Introduction
Despite increased focus on early detection, most patients with non-small cell lung cancer (NSCLC)
present with advanced disease, i.e., they are inoperable and a cure is extremely rare [1]. If not eligible for
first-line targeted therapy or immunotherapy, these patients may be offered palliative chemotherapy
with cisplatin or carboplatin combined with a third-generation drug, e.g., pemetrexed, paclitaxel,
or vinorelbine. Response during chemotherapy is evaluated by tumor shrinkage on computed
tomography (CT) after two or three cycles of chemotherapy in agreement with the response evaluation
criteria in solid tumors (RECIST) [2]. As each treatment cycle usually lasts for three weeks, the first
response evaluation is typically carried out eight to twelve weeks after the initiation of cytotoxic
treatment. The median survival time for patients with advanced NSCLC is 3–4 months without
treatment and about 10–11 months when receiving palliative chemotherapy [1]. Further improvement
in survival for this group of patients will require new treatment strategies [3] and more efficient
follow-up to make the right decisions about which patients would benefit from chemotherapy and
who are unlikely to benefit and should be spared the side effects. Early evaluation of treatment
response enabling modification of ineffective treatment regimens is therefore of great interest.
The combination of positron emission tomography and computed tomography with
18F-fluorodeoxyglucose (FDG-PET/CT) has been a game changer in diagnosis, staging, and treatment
planning in cancer patients since its introduction in 2001 [4,5] and is a well-documented and widely
used imaging modality for the diagnosis and staging of patients with lung cancer [6,7]. However,
despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, it
is rarely used for response evaluation in lung cancer. The true value of FDG-PET for monitoring
treatment response is impeded by the diversity and heterogeneity of the published data [8], including
challenges associated with standardization of fasting, timing between injection and scan as well as
differences in changes in FDG uptake depending on the type of therapy [9–11]. Further, some studies
have discouraged the use of FDG-PET earlier than 2 weeks after last chemotherapy due to the risk of
flare [12]. Few studies have actually investigated the correlation between FDG uptake, and possible
response and timing of PET after therapy [13]. The recommendations are based on in vitro studies and
studies in mice with implanted tumors, suggesting the existence of (1) a flare-phenomenon [14–17]
where an increased uptake of FDG in the cells is seen as a short-term effect of the treatment without
reflecting lack of efficacy, and (2) stunning, where the retention of FDG in malignant cells temporarily
decreases without a reflecting response [18].
No conclusive data on the optimal interval between chemotherapy and FDG-PET scan have yet
been published. Nonetheless, these early and scarce data still have a huge impact on the possible use
of FDG-PET for response evaluation in solid tumors, discouraging very early response evaluation and
obstructing smooth logistics.
The combination of PET and magnetic resonance imaging (MRI), PET/MRI, was introduced in
2010 as an integrated clinical imaging modality [19–21]. Compared to PET/CT, the PET/MRI system
enables radiation dose reduction, improved soft-tissue contrast and importantly simultaneously
acquisition of information on tumor anatomy and several functional parameters [19,21,22]. However,
without a CT transmission scan, a major technical challenge for PET/MRI is attenuation correction.
Methods, implemented clinically, to overcome this result in incorrect PET quantification [23]. In this
respect, diffusion-weighted MR imaging (DW-MRI) is a widely used non-invasive, quantitative
technique that, similar to FDG-PET, has shown promise as a tool in early response evaluation of
cytotoxic treatment [24]. DW-MRI has gained increasing use in staging and therapy evaluation
of cancer [25,26]. DW-MRI reflects the cell density and is based on diffusion of water molecules
in tissues [27]. DW-MRI can be quantified by calculation of ADC (apparent diffusion coefficient).
The more undamaged cells in a tissue, the higher the restriction of water diffusion and the lower the
value of ADC.
The overriding aim of this study was to explore if very early (i.e., within the first week of treatment)
response evaluation using multi-parametric imaging is possible. As a first step, this pilot study was
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performed with the following three-fold purpose: (A) to test the feasibility of repeated PET/MR early
during chemotherapy, (B) to examine whether the information on tumor characteristic simultaneously
acquired on FDG-PET and DW-MRI reveals patterns that potentially enable us to predict responses very
early during therapy and (C) to explore the postulated existence of a flare-phenomenon in malignant
lung tumors early during chemotherapy, which could potentially exclude early response evaluation.
2. Methods
2.1. Study Population
Patients with advanced NSCLC referred to the Department of Oncology at Rigshospitalet
(Copenhagen, Denmark) for standard first line palliative chemotherapy with carboplatin and
vinorelbine were included. Patients in performance status 0–1, with no known contraindications
to MRI, could enter the study before the first or the second cycle of chemotherapy.
Patients were asked to undergo up to five FDG-PET/MR scans during one cycle of chemotherapy:
Scan 1: 0–3 days prior to initiation of chemotherapy, Scan 2: day 1–3 after chemotherapy, Scan 3: day 6
or 7 (prior to administration of oral vinorelbine on day 8), Scan 4: day 8–11, and Scan 5: day 18–21
(1–2 days prior to initiating the next cycle). The study was approved by the departmental science
committees at Rigshospitalet, by the Regional Ethics Committee, approval number H-3-2013-090, and
by the Danish Data Protection Agency.
2.2. Imaging
All patients were scanned on an integrated PET/MR system (Siemens Biograph mMR, Erlangen,
Germany) with a 3 Tesla magnet using a combination of spine and flexible body coils. Patients were
instructed to fast for minimum six hours prior to attendance. They were scanned 60 min after injection
of FDG (2 MBq/kg).
PET was performed over 2 bed-positions covering the chest and upper abdomen, each
bed-position with 8 min acquisition time. MRI included the following sequences: T1 VIBE transaxial,
T2 HASTE transaxial and T2 BLADE coronal (all in breath hold) and Dixon for MR-based attenuation
correction (MR-AC) of PET data. The Dixon sequence was repeated twice without repositioning,
resulting in two (A and B) MR-AC maps [28]. DW-MRI was acquired using a single-shot EPI
with b-values 150 and 1000, TR = 10300 ms, TE = 73 ms, parallel imaging factor = 2, voxel size
3.0 × 3.0 mm2, slice thickness/gap 5/1 mm, 34 slices/bed. EPI distortions were corrected using FSL
(www.fmrib.ox.ac.uk/fsl) with FUGUE algorithm. The pre-therapy scan was performed after injection
of iv gadolinium contrast agent (0.1 mL/kg, Gadovist 1 mmol/mL, Bayer, Berlin, Germany) before
acquisition of a T1 VIBE fat saturated transaxial MRI sequence.
PET data was reconstructed using 3-dimensional ordinary Poisson ordered-subset expectation
maximization with 3 iterations, 21 subsets, and 4-mm Gaussian post filtering on 344 · 344 · 224 matrices
with a voxel size of 2.1 · 2.1 · 2.0 mm.
2.3. PET/MRI Reading and Data Extraction
Two experienced PET/MR physicians reviewed all MR-AC maps. In general, MR-AC map A
was used for attenuation correction of the PET images. MR-AC map B was used for attenuation
correction only if MR-AC map A was subjected to artifacts, and MR-AC maps B was not. Differences
between the MR-AC maps were mainly caused by as respiration motion and patient movement during
scan (described in details by Olin et al. [28]). The tumor volumes (primary T-site) were defined and
segmented on DW-MRI and PET images by an experienced radiologist respectively nuclear medicine
physician. This was done using image analysis tool Mirada XD3 (Mirada Medical, Oxford, UK) and the
following parameters were extracted: SUVmax, SUVmean (maximum and mean standardized uptake
value normalized to injected dose and body weight), PERCIST measures [29] including SULpeak (peak
standardized uptake value normalized to injected dose and lean body mass), liver reference uptake
Diagnostics 2019, 9, 35 4 of 13
and standard deviation as well as tumor size (longest diameter on axial T2 images), and ADCmean and
ADCmedian (mean and median ADC acquired from ADC maps based on b150–b1000).
Standardized uptake values were calculated as follows:
SUV =
r( a ′
w
) (1)
For calculating SUVmax, r is the maximum radioactivity activity concentration [kBq/mL]
measured by the PET scanner in any voxel within the tumor. For SUVmean r is the mean radioactivity
activity concentration [kBq/mL] measured in the tumor. a′ is the decay-corrected amount of injected
radiolabeled FDG [kBq], and w is the weight of the patient in grams.
For SULpeak, r is the radioactivity concentration averaged with a 10-mm-diameter spherical
ROI positioned by the MIRADA software (https://mirada-medical.com) within the tumor so as to
maximize the enclosed average. Instead of normalizing to the weight of the patient, the lean body
mass (LBM) of the patient was inserted in the above formula.
2.4. Statistical Analysis
The study was designed as a feasibility study. In order to enable an examination of trends in SUV
and ADC parameters over several time points in a Linear Mixed Model, the inclusion of 10 patients
was estimated as the minimum requirement.
Descriptive statistics were reported as mean ± SD for normally distributed data and median
with inter quartile range for skewed data. A visual inspection of histograms was used to assess
normal distribution of data. If normal distribution was not met, data was transformed using the
natural logarithm prior to analysis. Possible correlations between variables were evaluated using
Pearson’s correlation coefficient. A Standard Linear Mixed Model (LMM) with scan as fixed effect and
subject as random effect was applied, analyzing potential changes in outcome over time. The LMM
implicitly imputes missing values and provides optimal unbiased inference for longitudinal data
under the assumption that missing data is missing at random. To examine possible response patterns,
the datasets were stratified into response categories according to RECIST 1.1 criteria based on CT
evaluation after 2–3 cycles of therapy, and, into 1st cycle patients and 2nd cycle patients. For PET the
PERCIST criteria was applied in which a decrease in SULpeak equal to or greater than 30% (and at least
0.8 SUL unit) equals partial metabolic response, a similar increase of at least 30% equals progressive
metabolic disease and changes in SULpeak within± 30% indicates stable metabolic disease [29]. Similar
recommendations are not available for DW-MRI, but based on the recent work by Weller et al. [30]
we chose an increase in ADC values equal to or greater than 25% as indicative of response, values
between ± 25% as no change, and a decrease in ADC greater or equal to 25% as progression. Data
handling and statistically analyses were performed using SPSS (IBM corporation, Armonk, NY, USA,
version 6.3), the LMM analyses were performed with SAS statistical software (SAS Enterprise guide
version 6.1, SAS Institute Inc, Cary, NC, USA). P-values below 0.05 was valued significant. However,
since this study was designed as a feasibility study, differences attaining a higher level of significance
(p < 0.1) are also reported and no correction for multiple comparisons was made.
3. Results
3.1. Patients
Successive patients referred from October 2013 to September 2015 for treatment of stage IV NSCLC
were pre-screened. After screening at first visit, 81 patients were found eligible. Informed consent was
obtained from 29, whereas 52 declined. Among the 29 patients, 16 patients were cancelled before or
during the first scan due to logistical or technical problems. Two patients got anxious in the scanner
and were excluded. Thus, eleven patients with stage IV NSCLC completed at least two scans. Patient
characteristics are summarized in Table 1. All patients were followed up with an evaluating CT as part
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of the standard program after two or three cycles of chemotherapy in agreement with the response
evaluation criteria in solid tumors (RECIST 1.1). All patients were followed until death or for at least
24 months.
Table 1. Patient characteristics.
Patient Data N (%)
Sex (male/female) 7 (64)/4 (36)
Mean age (range) 62 years (52–73)
Histology (Adenocarcinoma/squamous cell carcinoma) 7 (64)/4 (36)
Chemotherapy cycle (first/second) 6 (54)/5 (46)
Response at CT evaluation (CR /PR /SD /PD) * 0 (0)/1 (9)/5 (45)/5 (45)
* Response according to RECIST 1.1: CR, Complete Response. PR, Partial Response. SD, Stable Disease. PD,
Progressive Disease.
3.2. PET/MR-Scans
A total of 45 PET/MRI scans were performed. Six patients were scanned during the first cycle
of chemotherapy, five during the second cycle. Table 2 summarizes the timing of the scans among
patients, as well as the percentage of attendance. All PET/MR scans were completed successfully
except DW-MRI on day 2 in patient number 1. Artifacts were seen in the MR-AC map A but not in
map B in 4 patients. In these cases, the MR-AC map B was used for attenuation correction. Tumor size
measured on MR decreased slightly but significantly from scan 1 (day 1) to scan 5 (day 19). There was
no significant correlation between any SUV and ADC measures. However, ADCmean and ADCmedian
were strongly correlated (ρ = 0.987, p < 0.001). Similarly, the three SUV measures (SUVmean, SUVmax
and SULpeak) correlated strongly (ρ ≥ 0.9, p < 0.001). Thus, in the following only results for ADCmedian,
SUVmax and SULpeak will be presented. ADCmedian was chosen over ADCmean, as this value is
less sensitive to noise and e.g pixels with ADC = 0 (due to missing signal). SUVmax was chosen as
this is the most frequently reported SUV measure in the literature, also it is known to be robust with
regard to segmentation and interobserver variability. However, since the size of a single voxel varies
considerably among PET systems and results in various noise levels in the metric, SUVmax is subject to
bias favoring the use of SUVpeak. SULpeak is also the recommend measure for quantification of changes
in FDG-uptake according to PERCIST (PET response criteria in solid tumors) [29].
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Figure 1. Changes in (A) FDG-uptake measured as SULpeak and (B) ADCmedian during the study period. 
Changes are presented for individual patients as percent difference with scan 1 as baseline. Dotted 
lines with circular markers indicate that the patient obtained stable disease or partial response (patient 
1). Solid lines with triangular markers indicate patients with progressive disease. 
3.3. Changes in SUV 
Illustration of absolute SUV-values and relative changes for individual patients during the 
course of therapy are available in Appendix 1 (Supplementary file). Inspection of histograms (not 
shown) revealed that SUV-data were almost normally distributed. Deviation from normality was due 
to a few outliers and did not improve after transformation.  
Figure 1A illustrates changes in FDG-uptake during the study period for individual patients. 
Table 3 illustrates mean and standard deviation for SUV values at each time point for all patients and 
grouped by response respectively whether patients were scanned during first or second cycle of 
chemotherapy. Due to the low number of patients in each group no statistical comparison between 
groups was performed, but results suggest higher SUV-values and more pronounced changes in 
patients scanned during the first treatment cycle as compared to second cycle. 
The LMM analysis revealed a small but significant fall (all patients) in both SUVmax (−1.8, 95% 
Confidence interval (CI) (−3.4; −0.2), p = 0.03) and SULpeak (−1.2, 95% CI (−2.1; −0.3), p = 0.01) from scan 
1 (prior to treatment) to scan 5. The change in SUV measured on scan 5 and scan 2 or scan 3 was not 
significantly different. However, the change measured on scan 4 tended to be smaller and more 
positive (increasing SUV from scan 1 to scan 4) than the changes measured on scan 5 (p = 0.04 and 
0.03 for SUVmax respectively SULpeak). 
In Table 4 patients are listed according to survival, best response on CT after therapy and 
changes in early respectively late ADC and SUV. SUV decreases tended to indicate long survival. 
E.g., all patients with a survival longer than 6 months had an unchanged or decreasing SULpeak and 
SUVmax (not shown) at the early PET/MR scan. On the later scan the majority of patients had a 
decreasing or unchanged SUV, independently of later response and survival.  
Table 3. FDG-uptake in tumor during chemotherapy. 
SUVmax 
mean (SD) 
All patients 
n = 11 
1. cycle 
n = 6 
2. cycle 
n = 5 
PR a 
n = 1 
SD b 
n = 5 
PD c 
n = 5 
Scan 1 9.9 (3.6) 10.6 (2.9) 9.0 (4.6) 15.2 9.8 (4.4) 8.8 (2.2) 
Scan 2 8.5 (1.9) 9.8 (1.2) 6.5 (0.9) 10.6 7.6 (2.2) 8.7 (1.8) 
Scan 3 8.7 (2.1) 10.4 (1.7) 7.4 (1.4) 10.9 9.1 (2.9) 7.6 (0.9) 
Scan 4 9.9 (3.4) 10.8 (1.9) 9.0 (3.4) 10.3 10.9 (3.8) 8.5 (3.2) 
Scan 5 8.6 (2.8) 9.0 (1.3) 8.2 (4.5) 8.3 9.9 (2.6) 6.3 (3.0) 
Figure 1. Changes in (A) FDG-uptake measured as SULpeak and (B) ADCmedian during the study
period. Changes are presented for individual patients as percent difference with scan 1 as baseline.
Dotted lines with circular markers indicate that the patient obtained stable disease or partial response
(patient 1). Solid lines with triangular markers indicate patients with progressive disease.
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Table 2. Timing and completion of chemotherapy and PET/MR scans.
Day −3 −2 −1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
week 1 2 3
Car a X
Vin b X X
PET/MR Scan 1 Scan 2 Scan 3 Scan 4 Scan 5
N (%) 11 (100) 10 (91) 7 (64) 10 (91) 7 (64)
Med c −1 (−3 to 0) 1 (1 to 3) 6 (6 to 7) 10 (8–11) 19 (16–21)
a Treatment with carboplatin intravenous (i.v). b Treatment with oral vinorelbine (p.o). c Median day and range for
performance of PET/MR.
3.3. Changes in SUV
Illustration of absolute SUV-values and relative changes for individual patients during the course
of therapy are available in Appendix ??. Inspection of histograms (not shown) revealed that SUV-data
were almost normally distributed. Deviation from normality was due to a few outliers and did not
improve after transformation.
Figure 1A illustrates changes in FDG-uptake during the study period for individual patients.
Table 3 illustrates mean and standard deviation for SUV values at each time point for all patients
and grouped by response respectively whether patients were scanned during first or second cycle of
chemotherapy. Due to the low number of patients in each group no statistical comparison between
groups was performed, but results suggest higher SUV-values and more pronounced changes in
patients scanned during the first treatment cycle as compared to second cycle.
The LMM analysis revealed a small but significant fall (all patients) in both SUVmax (−1.8, 95%
Confidence interval (CI) (−3.4; −0.2), p = 0.03) and SULpeak (−1.2, 95% CI (−2.1; −0.3), p = 0.01) from
scan 1 (prior to treatment) to scan 5. The change in SUV measured on scan 5 and scan 2 or scan 3 was
not significantly different. However, the change measured on scan 4 tended to be smaller and more
positive (increasing SUV from scan 1 to scan 4) than the changes measured on scan 5 (p = 0.04 and 0.03
for SUVmax respectively SULpeak).
In Table 4 patients are listed according to survival, best response on CT after therapy and changes
in early respectively late ADC and SUV. SUV decreases tended to indicate long survival. e.g., all
patients with a survival longer than 6 months had an unchanged or decreasing SULpeak and SUVmax
(not shown) at the early PET/MR scan. On the later scan the majority of patients had a decreasing or
unchanged SUV, independently of later response and survival.
Table 3. FDG-uptake in tumor during chemotherapy.
SUVmax
Mean (SD)
All Patients
n = 11
1. Cycle
n = 6
2. Cycle
n = 5
PR a
n = 1
SD b
n = 5
PD c
n = 5
Scan 1 9.9 (3.6) 10.6 (2.9) 9.0 (4.6) 15.2 9.8 (4.4) 8.8 (2.2)
Scan 2 8.5 (1.9) 9.8 (1.2) 6.5 (0.9) 10.6 7.6 (2.2) 8.7 (1.8)
Scan 3 8.7 (2.1) 10.4 (1.7) 7.4 (1.4) 10.9 9.1 (2.9) 7.6 (0.9)
Scan 4 9.9 (3.4) 10.8 (1.9) 9.0 (3.4) 10.3 10.9 (3.8) 8.5 (3.2)
Scan 5 8.6 (2.8) 9.0 (1.3) 8.2 (4.5) 8.3 9.9 (2.6) 6.3 (3.0)
SULpeak
Mean (SD)
All Patients
n = 11
1. Cycle
n = 6
2. Cycle
n = 5
PR
n = 1
SD
n = 5
PD
n= 5
Scan 1 5.8 (2.3) 6.5 (2.4) 5.1 (2.0) 10.8 5.5 (1.9) 5.1 (1.5)
Scan 2 5.0 (1.2) 5.7 (1.0) 4.1 (0.7) 6.8 4.6 (1.3) 5.0 (1.0)
Scan 3 5.3 (1.5) 6.5 (1.4) 4.4 (0.7) 7.6 5.3 (1.7) 4.5 (0.7)
Scan 4 5.8 (1.8) 6.6 (1.3) 5.0 (2.0) 6.9 6.1 (1.9) 5.1 (1.9)
Scan 5 5.0 (1.4) 5.4 (0.5) 4.5 (2.2) 5.8 5.4 (1.2) 3.8 (1.5)
a Partial Response according to RECIST 1.1, measured on CT after two-three cycles of chemotherapy. b Stable
Disease according to RECIST 1.1, measured on CT after two-three cycles of chemotherapy. c Progressive Disease
according to RECIST 1.1, measured on CT after two-three cycles of chemotherapy.
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3.4. Changes in ADC
Illustration of absolute ADC-values (mean and median) and relative changes for individual
patients during the course of therapy are available online (Online Resource 1). Inspection of histograms
and Q-Q plots revealed that ADC-data were not normally distributed, thus a log-transformation was
applied prior to analyses. Figure 1B illustrates changes in ADC during the study period for individual
patients. Table 5 illustrates median values and quartiles for ADCmedian at each time point for all
patients and grouped by first or second cycle of chemotherapy and response. Due to the low number
of patients in each group no statistical comparison between groups was performed, but results indicate
higher ADC-values in patients scanned during the first treatment cycle as compared to second cycle
and in patients with PD compared to patients with SD and PR. There was no significant change in
ADCmedian from scan 1 (prior to treatment) to scan 5 (day 19 and always prior to initiation of the next
cycle) (p = 0.73). Similarly, the difference in ADCmedian on scans 2, 3 and 4 as compared to scan 5 was
not significant. However, as illustrated in Table 4, a small decrease in ADC was more often seen in
patients with a survival of 6 months or less.
Table 4. Survival and early response on PET/MR.
Patient Survival * RECIST ˆ Early ADC † Early SUV ‡ Late ADC § Late SUV **
5 Alive NC
4 15 NC
1 12 PR
10 20 PD
2 10 NC
7 8 NC
11 6 NC
8 3 PD
9 3 PD NA NA
6 2 PD
3 1 PD
* Months from inclusion (date of chemotherapy) to death. † ADCmedian at scan 2 or 3 after chemotherapy. Red = >25%
decrease, Green = >25% increase, beige = no change. Arrows indicates changes smaller than 25% but larger than
10%. Please note increasing ADC indicates response. ‡ SULpeak at scan 2 or 3 after chemotherapy. In patient no. 9
SULpeak and SUVmax increased > 25%, Red = >30% increase, Green = >30% decrease, beige = no change. Arrows
indicates changes smaller than 30% but larger than 10%. decreasing SUV indicates response. § ADCmedian at scan
4 or 5 compared to baseline. Red = >25% decrease, Green = >25% increase, beige = no change. Arrows indicates
changes smaller than 25% but larger than 10%. ** SULpeak at scan 4 or 5 compared to baseline. In patient no. 9
SULpeak and SUVmax increased > 25%, Red = >30% increase, Green = >30% decrease, beige = no change. Arrows
indicates changes smaller than 30% but larger than 10%. ˆ PD = Progressive Disease; CR = Complete response;
change; NA = Not applicable.
Table 5. Diffusion in tumor during chemotherapy.
ADCmedian ††
Median (Q1; Q3)
All Patients
n = 11
1. Cycle
n = 6
2. Cycle
n = 5
Scan 1 1153 (1081; 1207) 1190 (1038; 1348) 1122 (1029; 1454)
Scan 2 1201 (964; 1439) 1216 (1048; 1547) 1058 (906; 1339)
Scan 3 1312 (1133; 1401) 1312 (1231; na **) 1267 (954; 1640)
Scan 4 1315 (987; 1483) 1350 (1126; 1535) 1119 (933; 1486)
Scan 5 1273 (1134; 1553) 1230 (1147; 1647) 1421 (934; na)
ADCmedian
Median (Q1; Q3)
PR
n = 1
SD
n = 5
PD
n = 5
Scan 1 1093 1153 (1029; 1196) 1194 (998; 1762)
Scan 2 - * 1117 (906; 1212) 1425 (989; 1547)
Scan 3 1231 1312 (894; na) 1390 (1133; na)
Scan 4 1431 1313 (991; 1334) 1321 (954; 1650)
Scan 5 1134 1230 (997; 1385) 1662 (1553; na)
†† Unit 10−6 mm2/s.* No data available due to technical challenges.** Not applicable.
Diagnostics 2019, 9, 35 8 of 13
4. Discussion
This prospective study assessed the feasibility and evolution of FDG-uptake and diffusion in
11 patients with NSCLC scanned up to five times during one cycle of chemotherapy, including a
total of 45 PET/MR scans. The study was performed in order to explore the technical feasibility of
repeated PET/MR very early during chemotherapy and the existence of multi-parametric patterns,
potentially enabling us to predict a response very early during therapy, with a special focus on the
possible existence of flare potentially hampering the use of early response evaluation.
4.1. Feasibility
The study was performed as a prospective feasibility study, generating basic knowledge and
methods as a platform for future prospective studies on the use of multi-parametric imaging with
PET/MR in tumor response evaluation. The study proves that it is challenging to schedule five scans
in three weeks during chemotherapy for patients newly diagnosed with a severe illness and with
short life expectancy. Moreover, technical challenges primarily related to the attenuation correction of
PET-scan based on MR-Dixon sequence was also experienced, these are reported in detail in a separate
technical paper [28]. In short, the Dixon-AC maps were often flawed by artifacts with potential impact
on the quantification of FDG-uptake. Thus, Dixon-AC maps should always be inspected prior to any
quantification on PET-images. Further, it might be useful to obtain two or more Dixon-AC maps to
improve quality of the quantification. Another limitation of the PET attenuation correction performed
here is that the flexible MR coils were not considered [31,32]. The coil attenuation depends on axial
position, which may vary between examinations, and on distance to the coil. The resulting potential
variation in the bias of PET activity values has been estimated to 0.9%–2.2% (standard deviations)
corresponding to a random coil positioning for repeated examinations [32]. While this worst-case
variation is much smaller than the percent changes observed, coil attenuation correction could be
worthwhile for future studies [33].
In 1999 European Organization for Research and Treatment of Cancer (EORTC) published
guidelines for measurement of clinical and subclinical tumor response using FDG-PET [34].
In 2009 a new set of guidelines Positron Emission Tomography Response Criteria in Solid Tumors
(PERCIST) [29,35] was proposed and even though the acceptance of these criteria have been quite
slow, recent publications support the use of PERCIST over the more simple EORTC criteria [36–49].
This study applied, for the first time in a PET/MR setting, PERCIST measurement. Among other things
PERCIST requires stable measurements of a reference SUL in the liver. Despite known challenges with
attenuation correction [40], we obtained relatively stable reference values in all patients except patient 3,
where measurement was hampered due to several liver metastases (Appendix 1, Supplementary File).
With the precaution of this being a very small study, we believe that PERCIST can also be adopted for
response evaluation with PET/MR.
4.2. Response Patterns and Flare
The rationale for using functional imaging, such as FDG-PET and DW-MRI, is the ability of
these modalities to detect functional changes in the tumor tissue prior to any changes observed by
anatomical measures [39]. Our findings partly support this hypothesis; all tumors decreased in size
during therapy (independent of later response), but these changes were very small and occurred later
than observed changes in SUV and ADC. This is also confirmed by another recent study applying
FDG-PET/MR for very early response evaluation [41].
It has been reported that SUV values obtained from tumor areas typically decrease following
effectively intervention in solid tumors. However, studies have described a temporary increase in SUV,
a flare, shortly after chemotherapy administration due to cell swelling, fibroblasts and macrophage
infiltration despite therapeutic effect [13,42,43]. Thus, it is currently a widely hold opinion that
differentiating between increased FDG uptake due to flare and true disease progression may not
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be possible early after chemotherapy. The result of this is the current recommendation to postpone
an FDG-PET scan to 10–14 days after chemotherapy. In this study we did not find any significant
difference between the response measured by SUV or SUL during the first week after therapy (scan 2
and 3) and immediately prior to the next cycle (scan 5, week 3). However, more unstable results were
seen on scan 4 (week 2) that could indicate the existence of a flare phenomenon at this time point.
This finding indicates that early response evaluation is probably best done immediately after or prior
to the next cycle of therapy, and that response measured halfway between two cycles might be unstable.
However, as this study is small and exploratory, the significant difference observed at scan 4 could be a
chance finding due to multiple testing. Thus, confirmation in larger studies is clearly needed. Response
assessment after treatment with the more recently introduced immune check-point inhibitors, was
beyond the scope of this paper, nonetheless newer research indicates that early response evaluation
may also be possible in this setting despite the risk of flare [44,45].
Earlier studies on DW-MRI reports that ADC values, representing tumor areas, typically increase
following effective intervention. However, as reviewed by Galban et al. [46], an initial decrease,
followed by an increase in ADC measurements can correlate with a positive response. The initial
decrease in ADC values can be a consequence of cell swelling followed by a later cell death causing
the ADC values to increase. Later fibrotic changes can again cause ADC values to decrease. Thus,
timing of DW-MRI after therapy is crucial, but studies with repeated DW-MRI measurements during
chemotherapy are lacking. In this study we did not observe the proposed pattern of initial decrease
followed by an increase in ADC. But a decrease in ADC value, both early and late, was observed more
frequently in patients surviving 6 months or less. However, as opposed to the majority of previously
published studies on early DW-MRI for response evaluation, we did not observe any significant
changes in ADC values during the course of treatment. Our results together with the results of similar
study done in patients with lymphoma, indicates that response is probably seen slightly later with
DW-MRI as compared to FDG-PET [42]. Early response evaluation in the literature tends to be done
after, rather than during the first cycle of chemotherapy [24,47–49] and together with the relatively low
number of observations in our study, this could be a possible explanation for this difference.
The changes observed at the very early as well as later scans in this study with regard to both SUV
and ADC, were generally small and smaller than the recommended cut-off points of respectively 30%
in PERCIST and the applied 25% for ADC [29,30]. Under due consideration of the test-retest stability
of the individual methods, this indicates that different cut-off points should be tested for very early
response evaluation, which has also been suggested in the original EORTC response criteria and most
recently by Cho and colleagues [34,45].
In this study patients were included prior to the first or the second cycle of chemotherapy.
Our results indicate that, for both FDG-PET and DW-MRI, the response signal measured during the
first cycle of chemotherapy is more pronounced than during the second cycle. This is in line with the
findings reported by Nahmias and colleagues. Performing up to seven FDG-PET scans during the first
two cycles of chemotherapy, they found that responses are achieved after one cycle of chemotherapy
and that responses are less predictable with further chemotherapy cycles [50].
In summary, even though this study included a relatively small number of patients and
results should be interpreted with caution, our results raise several important points: Repeated
multi-parametric imaging by PET/MRI during chemotherapy in newly diagnosed lung cancer patients
is challenging. Quantification of FDG-uptake on PET/MR requires caution with regard to the quality of
attenuation correction; nonetheless the application of PERCIST appears feasible. Response evaluation
shortly after initiation of therapy is concordant with later evaluation and probably more reliable
than evaluation midway between chemotherapy cycles. Last, but not least, responses are likely to be
achieved and more readily measured during or after the first cycle of chemotherapy rather than during
subsequent cycles. We are currently initiating a larger study using PET/CT to confirm or disprove
these findings in patients treated with chemotherapy and also with other treatment regimens, i.e.,
immune checkpoint inhibitors.
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